Jobs
View more job listings or post a job
MilliporeSigma Emerging Biotech Market Development Manager - San Fransisco
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Post a job

Symposium

[Free Online] Innovative Mass Spectrometry and Related Technologies for Life Science and Drug Development


Speakers: Sven Hackbusch, Thermo; Gabriel Bracamontes, Evosep; Frederick Strathmann, MOBILion; Jim Lau, Agilent; Daojing Wang, Newomics; Eshani Galermo, Sciex; Stephen English, Pharmaron
Organizers: John Mehl (Agilent), Keyang Xu (Genentech)
Date: 2024-12-05
Time: 8:30-13:05 Pacific Time
Registration fee: 0
Location: Online via Zoom
Major Sponsor: (1)Thermo Fisher Scientific
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-12-04  (it will close sooner if the seating cap is reached)

About the Topic

The scope of mass spectrometry applications in life science and drug development has broadened significantly in recent years, thanks to continuous scientific innovation in MS and related technologies. For instance, quantitative MS-based or hybrid LC-MS bioanalytical assays are developed routinely to assess pharmacokinetic exposure in regulated studies, as well as measure biomarkers for target engagement, pharmacodynamic or safety effects. In addition, characterization of reference materials, catabolites and metabolites (both in vitro and in vivo), immunogenicity, and other parameters can also be achieved using MS-based approaches. Needless to say, limitations, challenges and new demands are identified in the process, which can be addressed via introduction and implementation of novel technologies in MS and peripheral devices. In this symposium, we aim to showcase some recent concepts and developments, primarily from instrument manufacturers/vendors, to further enhance MS-based assay performance, throughput, and problem-solving capabilities. Case studies will highlight faster and cleaner sample preparation, more selective analyte separation, robust/reproducible ionization and transmission, radiolabeled microtracer approach, complementary multiplexing ion detection, and optimized data handling in support of drug development of both small and large molecules.

Time (PST) Topic Presenter(s)
8:30 – 8:45 am PBSS Welcome and Introduction Shichang Miao, PhD, PBSS
8:45 – 9:15 am Increased Throughput of Simultaneous Stability Testing and MetID of Macrocyclic Peptide Drugs Enabled by Sample Multiplexing on a Fast and Sensitive Mass Spectrometer Sven Hackbusch, PhD, Senior Applications Scientist, Thermo Fisher Scientific
9:15 – 9:45 am A Complete and Automated End-to-End Sample Preparation Strategy for Standardized Proteomics Gabriel Bracamontes, MS, Product Specialist, Evosep Biosystems
9:45 – 10:15 am Achieving the Benefits of 2D Chromatography Without the Complexity: Advances in High-Resolution Ion Mobility (HRIM) Frederick Strathmann, PhD, MBA, DABCC, SVP of US Business, MOBILion Systems
10:15 – 10:45 am Applying Microdroplet Technology to Automate the Analysis of Intact Proteins by Mass Spectrometry Jim Lau, PhD, HRAMS LCMS Application Engineer, Agilent Technologies
10:45 – 10:55 am  Major Sponsor presentation Thermo Fisher Scientific
10:55 – 11:05 am  Break -
11:05 – 11:35 am  Multispray Technology for Native Mass Spectrometry for Studying Biomolecules Daojing Wang, PhD, Founder, President & CEO, Newomics
11:35 am – 12:05 pm Enhance Your Mass Spectrometry Data Analysis With New Innovative Tools to Advance Drug Discovery Eshani Galermo, PhD, Sr. Global Lead, Biopharma Quant and Pharma, SCIEX
12:05 – 12:35 pm Qualification of Low Energy Accelerator Mass Spectrometer and Opportunities to Increase Industry Utilization Stephen English, Director, 14C-Bioanalysis, Pharmaron
12:35 – 1:05 pm Panel Discussion All presenters 


2024-12-13, Why All These New Modalities?
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
2025-02-06, [In-Person] Intellectual Property (IP) Strategies and Best Practices
2025-02-26, [In-Person] Demystifying Biopharma Business Development
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
©Pharmaceutical & BioScience Society, International; Last Modified: 11/21/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Aroga Biosciences Aroga Biosciences is an award-winning CRO specializing in scientific writing for nonclinical reports, INDs, CMC, and clinical documents.
Allucent Bringing innovation to Biotech w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Aliri Bioanalysis to the rescue! Pioneers in LCMS & Oligo bioanalysis w/ 30+ years of experience putting dev. programs back on track with quality data & fast timelines.
Submit a Text Ad